Histotripsy at MountainStar Healthcare’s St. Mark’s Hospital
The future of non-invasive cancer therapy is bright. Liver tumors can now be destroyed—without radiation, chemotherapy or surgery—thanks to new...
The future of non-invasive cancer therapy is bright. Liver tumors can now be destroyed—without radiation, chemotherapy or surgery—thanks to new...
Elderly patients with MAFLD demonstrated insufficient knowledge, unfavorable attitudes, and limited proactive practices toward disease management, highlighting a significant gap...
Vantive, a company that provides vital organ therapies, announced it will invest more than $1 billion over the next five...
Antihemophilic Factor MarketOverview of the Antihemophilic Factor MarketThe global Antihemophilic Factor (AHF) market is experiencing robust growth, driven by rising...
MobiHealthNews’ Emerging Technologies Series will spotlight organizations developing, scaling and investing in innovative healthcare technologies. What follows is part one...
Listen to this article The basics: MASLD is most common liver disease in the U.S. New drugs and tech give...